Diagnostic value of S100P for pancreatic cancer: a meta-analysis

Abstract

Pancreatic cancer (PC) is a fatal disease with a high mortality and poor prognosis. PC is the fourth leading cause of cancer death in America, and 80 % of PCs are diagnosed at an unresectable stage. Effective early detection assays are crucial since a successful operation at early stage is the best strategy for this disease. S100 calcium-binding protein P (S100P) has been reported as a predictive diagnostic index for PC and involves in the development of PC. However, the diagnostic accuracy of S100P in detecting PC has never been systematically assessed. The aim of the present study was to evaluate the diagnostic performance of S100P for PC. All relevant original articles about S100P in the diagnosis of PC published up to December 2013 were retrieved. The methodological quality of each study was assessed by QUADAS. The overall diagnostic sensitivity, specificity, diagnostic odds ratio (DOR), with 95 % confidence interval (CI), and area under the receiver operating characteristic curve (AUC) were pooled to evaluate the diagnostic value of S100P for PC using the Meta-DiSc1.4 statistical software. Eight studies met our criteria in the present meta-analysis. The pooled sensitivity, specificity, and DOR calculated by the bivariate random effects model were 0.87 (95 % CI 0.83-0.90), 0.88 (95 % CI 0.82-0.93), and 38.32 (95 % CI 11.22-130.87), respectively. The summary receiver operating characteristic (SROC) curve was located near the desirable left corner and the AUC was 0.9272. The current evidence suggests that S100P plays an important role in the diagnosis of PC with a high sensitivity and specificity. S100P may be regarded as a promising diagnostic marker to PC screening.

The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas

“…S100P was observed in 95% of the cases of pancreatic ductal adenocarcinomas (84). S100P-containing staining patterns are suggestive of PDAC, and S100P was proposed a promising diagnostic marker in pancreatic cancer screening (85, 86). S100P binds and regulates IQGAP1 (87) as does CaM (88).…”

Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy

“…Indeed, mesothelin was detected in PDAC tissues but not in normal pancreas and chronic pancreatitis [23]. It was reported that significantly elevated levels of circulating mesothelin protein were detected in 73 of the 74 patients with pancreatic adenocarcinoma, and in all five patients with benign pancreatic disease, but not in the healthy controls [24] As the most of the other PDAC biomarkers, mesothelin is not a PDAC specific biomarker but can be combined with other biomarkers for confirming diagnosis of PDAC [25]. Recent studies have shed light on the possible role of mesothelin as an antigen for immunotherapy.…”

The role of S100 proteins and their receptor RAGE in pancreatic cancer

“…Its expression significantly increases in many solid tumors, including ovarian, prostate, gastric, colorectal, breast and pancreatic carcinomas [3, 30]. S100P is clinically used as a diagnostic marker of pancreatic ductal adenocarcinoma [31, 32]. …”